Phase IV randomized clinical study: Peginterferon alfa-2a with adefovir or entecavir pre-therapy for HBeAg-positive chronic hepatitis B.

CONCLUSION: Pre-therapy with ADV or ETV followed by PEG-IFN alfa-2a is not superior to PEG-IFN alfa-2a monotherapy in Taiwanese patients with HBeAg-positive CHB.
CLINICAL TRIAL ID: NCT: 00922207.
PMID: 29456079 [PubMed - as supplied by publisher]

Source: J Formos Med Assoc - February 15, 2018 Category: General Medicine Authors: Hsu CW, Su WW, Lee CM, Peng CY, Chuang WL, Kao JH, Chu HC, Huang YH, Chien RN, Liaw YF Tags: J Formos Med Assoc Source Type: research